IDH2 and central nervous system cancer: Mutations in the isocitrate dehydrogenase (IDH) genes, including IDH1 and IHD2, have been frequently identified in low-grade glioma, and correlate with favorable prognosis of patients (Agnihotri et al., 2014; Picca et al., 2018).